Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35results about How to "Good tumor growth" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer Metastasis Inhibitor
InactiveUS20120183539A1Promoted angiogenesisPromoted tumor growthImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHematopoietic cellLymphatic Spread
The present inventors used a model of intrasplenically induced liver metastasis to determine whether or not NF-κB activation in the liver is involved in the onset of metastatic tumors. When IKKβ was deleted from both liver cells and hematopoietically-derived cells, the onset of tumors was reduced remarkably. Tumor cells activated neighboring bone marrow cells (Kupffer cells) and produced mitogens such as interleukin (IL)-6, and this promoted angiogenesis and growth of tumors. The mitogen production depended on NF-κB in hematopoietically-derived Kupffer cells. Furthermore, treatment with an anti-IL-6 receptor antibody decreased the degree of metastatic tumor development. That is, the present inventors showed that tumor metastasis depends on inflammation, and proinflammatory intervention that targets Kupffer cells is useful for chemical prevention of metastatic tumors. Furthermore, it was shown that inhibition of the IKKβ / NF-κB signal transduction pathway, in particular IL-6 inhibition, can be utilized for anti-metastasis agents.
Owner:MAEDA CORPORATION
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
InactiveUS20170151281A1High proliferation rateIncrease productionPolypeptide with localisation/targeting motifPeptide/protein ingredientsIntracellular signallingDendritic cell
The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
Owner:MYELOID THERAPEUTICS INC
Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
InactiveUS20070105790A1Patient compliance is goodKept lowBiocideCarbohydrate active ingredientsATPaseAglycone
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+e / K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers. The subject Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.
Owner:BIONAUT PHARMA
Treatment of refractory cancers using Na+/K+-ATPase inhibitors
InactiveUS20080027010A1Improve stress responseGood tumor growthBiocideOrganic active ingredientsATPaseAglycone
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.
Owner:BIONAUT PHARMA
Microencapsulated human pancreatic carcinoma cells, and preparation method and application thereof
InactiveCN102337259AActive proliferationHigh tumor formation rateVeterinary instrumentsOn/in organic carrierMatrigelHuman pancreas
The invention discloses microencapsulated human pancreatic carcinoma cells, and a preparation method and application thereof. The preparation method comprises the following steps of: adding suspension with human pancreatic carcinoma cells into Matrigel-containing sodium alginate solution; spraying into a calcium chloride solution in high voltage electrostatic environment to obtain microspheres; and performing ion exchange reaction on the microspheres and a sodium citrate solution, and thus obtaining the microencapsulated human pancreatic carcinoma cells. The obtained microencapsulated human pancreatic carcinoma cells have uniform size and the diameter of about 420mm. Cells in microcapsules are well proliferated, and grow in a three-dimensional way. The microencapsulated human pancreatic carcinoma cells are applied to subcutaneous tumor and in-situ tumor animal models, and have the advantages of high modeling success rate and quick tumor growth compared with the traditional tumor cell suspension injection method.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Cancer metastasis inhibitor
InactiveUS20180222986A1Degree of reductionOnset of tumors was decreasedImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAbnormal tissue growthHematopoietic cell
Owner:MAEDA CORPORATION
Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
InactiveUS20040052810A1Potentiates plasminogen/plasmin conversionHigh activityHydrolasesPeptide/protein ingredientsAngiogenesis growth factorIn vivo
The present invention relates to novel nucleic acids encoding novel amino acid fragments of polypeptides, called abrogens. The present invention also relates to novel, potent in vitro and in vivo inhibitors of endothelial cell proliferation, and compositions of them and their use. The present invention further provides methods for modulating angiogenesis and / or inhibiting unwanted angiogenesis. Polypeptides according to the present invention are useful for developing cell growth-modulating compositions and methods and for treating and / or preventing cancer, tumor growth, or other angiogenic dependent or angiogenesis associated diseases.
Owner:GENCELL SA
Photosensitizer having dual photodynamic therapy effects and preparation method thereof
ActiveCN106581675AGood tumor growthGood light stabilityPhotodynamic therapyAntineoplastic agentsNear infrared irradiationCoordination complex
The invention discloses a photosensitizer having dual photodynamic therapy effects and a preparation method thereof, wherein the photosensitizer having the dual photodynamic therapy effects has the structural formula described in the specification. With cheap and easy-to-obtain 2-phenylpyridine, iridium trichloride and ethyl benzoate terpyridine as raw materials, and through mild reaction conditions, a target product-iridium complex is simply and efficiently synthesized. Research results indicate that the iridium complex has two-photon excited fluorescence emission in a near infrared region and can be used as a photosensitizer for photodynamic therapy. Confocal development is used for tracking the photodynamic therapy process, the photosensitizer iridium complex can be obviously observed to migrate from cell nucleuses to mitochondria under illumination, and secondary damage of the cells is caused. Animal experiments also prove that the iridium complex has quite good inhibitory effects on tumor growth under a near infrared irradiation condition and has low toxicity to animal bodies in dark environments.
Owner:合肥欧申福德生物科技有限责任公司
Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
InactiveUS20030228298A1Potentiates plasminogen/plasmin conversionHigh activityVirusesPeptide/protein ingredientsUrokinase Plasminogen ActivatorKringle domain
The invention relates to abrogen polypeptides and nucleic acids that encode them. In general, the abrogen polypeptides comprise the kringle domain from, for example, urokinase plasminogen activator. Abrogen polypeptides can be used to inhibit endothelial cell activation and / or proliferation and can inhibit endothelial cells activated or induced by both bFGF and VEGF. The invention also encompasses methods to produce polypeptides that possess abrogen activity as well as method for using these polypeptides.
Owner:AVENTIS PHARMA INC
Cancer treatment
InactiveUS6284799B1Improve inflammatory responseGood tumor growthBiocideAnimal repellantsMedicineCancer therapy
The present invention is concerned with the identification of compounds which increase the therapeutic index of chemotherapy drugs and which stimulate the growth of cancers, their use in the treatment of cancer and with certain novel compounds useful in such treatment.
Owner:UNIVERSITY OF MANITOBA
Traditional Chinese medicine preparation for treating leukemia and relieving side effects of chemotherapy
InactiveCN103263565AEasy to prepareWide range of medicinesImmunological disordersAntineoplastic agentsSide effectHouttuynia
The invention relates to a traditional Chinese medicine preparation for treating leukemia and relieving side effects of chemotherapy. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 200 parts of cistanche, 200 parts of Chinese Starjasmine Stem, 100 parts of cordate houttuynia, 50 parts of manyleaf paris rhizome, 15 parts of Oldenlandia diffusa, 15 parts of Sculellaria barbata and 5 parts of ginseng. The traditional Chinese medicine preparation disclosed by the invention is simple and convenient to prepare, is wide in drug source and low in cost and has a wide application prospect.
Owner:胡庆华
STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN
InactiveUS20120122771A1Strong specificityGood tumor growthNervous disorderPeptide/protein ingredientsLow affinityBinding site
The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly, the present invention relates to the crystal structure of the low affinity insulin binding site of the IR ectodomain comprising the C-terminal region of the IR α-chain, as well as the corresponding region of IGF-1R, and to methods of using the crystal and related structural information to screen for and design compounds that interact with or modulate the function of IR and / or IGF-1R.
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES
Method and composition for treating cancer using cellular organelle crystallizing agents
InactiveUS20060286170A1Effectively deliver high dosageSlow and sustained releasePowder deliveryBiocideAbnormal tissue growthMedicine
This invention provides a method for treating cancer in mammals through cellular-organelle-crystallization-induced-death (herein defined as “Cocid”), a method for treating cancer using cellular organelle and / or cytoskeleton crystallizing agents (e.g. tetrazolium salts and their derivatives), pharmaceutical compositions containing a therapeutically effective amount of organelle and / or cytoskeleton crystallizing agents, and compositions containing organelle and / or cytoskeleton crystallizing agents in combination with a pharmaceutically acceptable carrier, diluent or excipient. The crystallizing agents with or without a pharmaceutically acceptable carrier, diluent or excipient, are used in combination with surgery and / or non-surgical anti-tumor treatments.
Owner:KONG
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
InactiveUS20210252053A1High proliferation rateIncrease productionPolypeptide with localisation/targeting motifPeptide/protein ingredientsDendritic cellAntigen binding
The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
Owner:MYELOID THERAPEUTICS INC
Preparation method and application of diagnosis and treatment microbubbles based on Janus drug conjugates
ActiveCN109568610APrevent leakagePromote enrichmentOrganic active ingredientsEchographic/ultrasound-imaging preparationsUltrasound imagingMicrobubbles
The invention relates to multifunctional microbubbles integrating ultrasonic imaging and chemotherapy, and relates to a preparation method of the multifunctional microbubbles and application of the multifunctional microbbles to tumor diagnosis and treatment. The structure diagram integrating ultrasonic imaging and chemotherapy is shown in the figures, the membrane components of the microbubbles comprise Janus drug conjugates used for chemotherapy and conventional phosphatides, the proportions of the Janus drug conjugates and the conventional phosphatides can be regulated according to needs, and therefore the drug loading capacity is greatly improved. Under an ultrasonic effect, the purpose that designated targeted blasting is converted to nano particles at a tumor site can be achieved through the multifunctional microbubbles, so that the enrichment and uptake of drugs at the tumor site are greatly improved, and the effect of suppressing tumor growth through chemotherapy is greatly improved.
Owner:PEKING UNIV
Method and composition for treating cancer using cellular organelle crystallizing agents
InactiveUS6864272B2Effectively deliver high dosageSlow and sustained releaseBiocideOrganic chemistryAbnormal tissue growthMedicine
This invention provides a method for treating cancer in mammals through cellular-organelle-crystallization-induced-death (herein defined as “Cocid”), a method for treating cancer using cellular organelle and / or cytoskeleton crystallizing agents (e.g. tetrazolium salts and their derivatives), pharmaceutical compositions containing a therapeutically effective amount of organelle and / or cytoskeleton crystallizing agents, and compositions containing organelle and / or cytoskeleton crystallizing agents in combination with a pharmaceutically acceptable carrier, diluent or excipient. The crystallizing agents with or without a pharmaceutically acceptable carrier, diluent or excipient, are used in combination with surgery and / or non-surgical anti-tumor treatments.
Anti-tumor pharmaceutical composition based on macrophage effect blocking and application thereof
InactiveCN109999038ARestoring anti-tumor immune responsesGood tumor growthOrganic active ingredientsAntineoplastic agentsDrugT cell
The invention provides an anti-tumor pharmaceutical composition based on blocking macrophage effects and application thereof, and illuminates the biological mechanism of the anti-tumor pharmaceuticalcomposition in the tumor treatment process. The anti-tumor pharmaceutical composition based on macrophage effect blocking comprises an epigenetic inhibitor and a macrophage effect blocker. The drug can effectively recover anti-tumor immune response of T cells, and better inhibits the growth of tumor. Because the macrophage effects are blocked, the negative feedback effects brought by the epigenetic inhibitor are cleared away, the epigenetic inhibitor and the macrophage effect blocker are combined to generate a synergistic effect, and therefore, the drug has a good clinical application prospect.
Owner:SUN YAT SEN UNIV
2-Oxadiazolechromone derivatives
InactiveUS20040138464A1Not diminish their mitotic ratePromote angiogenesisBiocideOrganic chemistryStress ProteinsProtection Skin
Novel compounds of the formula I in which R, X and n are as defined herein, are inhibitors of tyrosine kinase and can be employed for the treatment of tumours, for neuroprotection and for protection of the stress proteins of the skin.
Owner:MERCK PATENT GMBH
Drug Resistance and Methods of Reversing
ActiveUS20090220427A1Reduce productionGood tumor growthMicrobiological testing/measurementDisease diagnosisDocetaxel-PNPCancer cell
Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.
Owner:YALE UNIV
Altering steroid metabolism for treatment of steroid-dependent disease
ActiveUS20160310509A1Good tumor growthOrganic active ingredientsPharmaceutical delivery mechanismDiseaseProstate cancer
Owner:THE CLEVELAND CLINIC FOUND +1
Compositions and methods for augmenting permeability barriers
ActiveUS20140256614A1Augmenting permeability barrierReducing leak）Antibacterial agentsBiocideEndothelial barrierDisease
Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and / or endothelial barriers, and treating diseases, conditions, disorders, and / or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein.
Owner:TUFTS MEDICAL CENTER INC
Tumor marker, monoclonal antibodies and methods of use thereof
InactiveUS20160131656A1Selective immunoreactivityEffective internalizingMicrobiological testing/measurementImmunoglobulins against cell receptors/antigens/surface-determinantsMonoclonal antibodyWilms' tumor
Newly identified proteins as markers for the detection of colon, ovary, kidney, esophagus and prostate tumors, or as therapeutic targets for their treatment; affinity ligands and particularly antibodies capable of selectively interacting with the tumor markers and methods for tumor diagnosis and thereapy using such antibodies.
Owner:EXTERNAUTICS
Structure of the C-terminal region of the insulin receptor α-chain and of the insulin-like growth factor receptor α-chain
InactiveUS8666718B2Strong specificityGood tumor growthNervous disorderAnalogue computers for chemical processesLow affinityBinding site
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES
Method and composition for treating cancer using cellular organelle crystallizing agents
InactiveUS7524872B2Effectively deliver high dosageSlow and sustained releasePowder deliveryBiocideAbnormal tissue growthMedicine
This invention provides a method for treating cancer in mammals through cellular-organelle-crystallization-induced-death (herein defined as “Cocid”), a method for treating cancer using cellular organelle and / or cytoskeleton crystallizing agents (e.g. tetrazolium salts and their derivatives), pharmaceutical compositions containing a therapeutically effective amount of organelle and / or cytoskeleton crystallizing agents, and compositions containing organelle and / or cytoskeleton crystallizing agents in combination with a pharmaceutically acceptable carrier, diluent or excipient. The crystallizing agents with or without a pharmaceutically acceptable carrier, diluent or excipient, are used in combination with surgery and / or non-surgical anti-tumor treatments.
Owner:KONG
Application of pigeon pea stilbene acid in the preparation of antitumor drug
ActiveCN101569654BMaintain ecological balanceEfficient and reasonable useOrganic active ingredientsAntineoplastic agentsBiotechnologyPharmaceutical drug
Owner:NORTHEAST FORESTRY UNIVERSITY +1
STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN
InactiveUS20140154817A1Strong specificityGood tumor growthNervous disorderMetabolism disorderLow affinityBinding site
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES
Method For Delivering Gene In Cells
PendingUS20220056479A1Many choicesGood curative effectImmunoglobulin superfamilyStable introduction of DNAGene deliveryBiological macromolecule
Disclosed is a method for delivering a gene into target cells, wherein immune cells are used as a vector for virus packaging and transportation to complete the delivery of biomacromolecules among cells, and thus change original characteristics of the target cells or generate new characteristics in the target cells. The gene delivery system, on one hand, can kill target cells such as tumor cells by utilizing the specificity of immune cells; and on the other hand, can modify genes of cells in a lesion by gene delivery to target cells, to directly kill the target cells.
Owner:CURE GENETICS CO LTD
Markers for alternatively activated macrophages
InactiveUS7514217B2Good tumor growthMicrobiological testing/measurementBiological material analysisSurface markerRapid identification
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
Traditional Chinese medicine preparation for treating leukemia and relieving side effects of chemotherapy
InactiveCN103263565BImprove anti-tumor effectGood tumor growthImmunological disordersAntineoplastic agentsSide effectHouttuynia
Owner:胡庆华
Application of non-metabolic function based on CHKalpha as target for cancer treatment, diagnosis and prognostic prediction
PendingCN113391069AImprove bindingEasy to synthesizeDisease diagnosisAntineoplastic agentsCholine kinaseLipolysis
The invention belongs to the technical field of tumor medicine, and relates to application of a non-metabolic function based on CHKalpha as a target for cancer treatment, diagnosis and prognosis prediction. According to the application disclosed by the invention, the tumor generation and development mechanism of choline kinase alpha (CHK alpha) in human cancers is analyzed, and a new action target is provided for cancer treatment, diagnosis and prognosis prediction by utilizing the effects of the non-metabolic function of CHKalpha in phosphatidylcholine synthesis regulation, glycometabolism (glycolysis), glutathione synthesis, lipid droplet lipolysis, beta-oxidation and tumor growth.
Owner:ZHEJIANG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com